APA (7th ed.) Citation

SL, T., M, S., DF, M., HM, K., RD, C., WH, S., . . . FS, H. (2023). Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 41(5), 943. https://doi.org/10.1200/JCO.22.02272

Chicago Style (17th ed.) Citation

SL, Topalian, et al. "Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 41, no. 5 (2023): 943. https://doi.org/10.1200/JCO.22.02272.

MLA (9th ed.) Citation

SL, Topalian, et al. "Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, vol. 41, no. 5, 2023, p. 943, https://doi.org/10.1200/JCO.22.02272.